VBI Vaccines Presents Early Tumor Response Data From Randomized Controlled Phase 2b Study Of VBI-1901 In Recurrent Glioblastoma; Early Data From Patients Eligible For Evaluation At Week 12 Show Two Observations Of Stable Disease, Indicating No Tumor Progression, In VBI-1901 Treatment Arm

4/3/24 8:07:13 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $VBIV alert in real time by email

Get the next $VBIV alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$VBIV

Date	Price Target	Rating	Analyst
11/11/2022	$5.00 → $2.00	Strong Buy → Outperform	Raymond James
3/8/2022	$9.00 → $6.00	Strong Buy	Raymond James
12/29/2021	$7.00 → $6.00	Buy	Jefferies

More analyst ratings

$VBIV
Press Releases

Fastest customizable press release news feed in the world

VBI Vaccines Provides an Update on its Restructuring Proceedings
VBI Vaccines Inc. (NASDAQ:VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today provided an update on the restructuring proceedings announced on July 30, 2024. U.S. Chapter 15 Filing On August 2, 2024, the United States Bankruptcy Court for the District of Delaware granted provisional relief under Chapter 15 of the U.S. Bankruptcy Code, and scheduled a further hearing to consider the recognition of the July 30, 2024, Ontario Superior Court of Justice (Commercial List) order ("Initial Order"), which granted the company protection under the Companies' Creditors Arrangement Act, R.S.C. 1985, c. C-36, as amended ("C
8/2/24 4:05:00 PM ET
$VBIV
Biotechnology: Pharmaceutical Preparations
Health Care
VBI Vaccines Initiates Restructuring Proceedings Under CCAA to Implement a Review of its Strategic Alternatives
VBI Vaccines Inc. (NASDAQ:VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that the Ontario Superior Court of Justice (Commercial List) ("Court") has issued an initial order ("Initial Order") granting the company protection under the Companies' Creditors Arrangement Act, R.S.C. 1985, c. C-36, as amended ("CCAA"). The Initial Order provides for, among other things: (i) a stay of proceeding in favour of VBI, (ii) approval of the DIP Loan (as described below), and (iii) the appointment of Ernst & Young Inc. ("EY") to serve as monitor ("Monitor") in the Court during the restructuring ("Restructuring Pro
7/30/24 9:55:00 AM ET
$VBIV
Biotechnology: Pharmaceutical Preparations
Health Care
VBI Vaccines Announces Results of Annual General Meeting
VBI Vaccines Inc. (NASDAQ:VBIV) ("VBI" or the "Company"), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced the voting results from its annual general meeting of shareholders held on June 25, 2024 (the "Meeting"). The total number of common shares of the Company ("Common Shares") represented by shareholders ("Shareholders") present in person or represented by proxy at the Meeting was an aggregate of 13,879,327 Common Shares, representing 48.39% of VBI's issued and outstanding Common Shares as of the record date for the Meeting, April 26, 2024. The voting results with respect to each of the following eight dir
6/25/24 4:15:00 PM ET
$VBIV
Biotechnology: Pharmaceutical Preparations
Health Care

$VBIV
Market Insights

Live Market Insights

VBI Vaccines Reports New Tumor Response Data From Ongoing Randomized Controlled Phase 2b Study Of VBI-1901 For Patients With Recurrent Glioblastoma
Among the 7 patients on VBI-1901 treatment long enough to have 1+ MRI scan at the time of analysis, one partial tumor response (PR) and two stable disease (SD) observations have occurred as of May 15, 2024The partial response, which demonstrated a 67% reduction in tumor size vs. baseline, was observed at week 6, after 2 doses of VBI-1901The disease control rate (DCR) in the VBI-1901 study arm was 43% (n=3/7) compared to 0% in the control arm (n=0/6) – n=5/6 patients in the control arm have experienced a 2-8x increase in tumor size vs. baseline and have been taken off study protocolFDA has granted both Fast Track Designation and Orphan Drug Designation to VBI-1901 in recurrent GBM following p
5/29/24 8:02:45 AM ET
$VBIV
Biotechnology: Pharmaceutical Preparations
Health Care
VBI Vaccines To Present New Interim Phase 2b Data From VBI-1901 In Recurrent Glioblastoma Patients In Poster Presentation At 2024 ASCO Annual Meeting
VBI Vaccines Inc. (NASDAQ:VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that new interim tumor response data from the ongoing randomized, controlled Phase 2b study of VBI-1901, the Company's cancer vaccine immunotherapeutic candidate in recurrent glioblastoma (GBM), were accepted for poster presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.The presentation at ASCO will provide an update to the encouraging data previously shared at the World Vaccine Congress Washington in April, including additional data from those initially evaluable patients, as well as data fro
5/22/24 8:04:09 AM ET
$VBIV
Biotechnology: Pharmaceutical Preparations
Health Care
VBI Vaccines Q1 EPS $(0.73) Up From $(3.22) YoY, Sales $1.21M Up From $485.00K YoY
VBI Vaccines (NASDAQ:VBIV) reported quarterly losses of $(0.73) per share. This is a 77.33 percent increase over losses of $(3.22) per share from the same period last year. The company reported $1.21 million in sales this quarter. This is a 150.31 percent increase over sales of $485.00 thousand the same period last year.
5/15/24 4:04:28 PM ET
$VBIV
Biotechnology: Pharmaceutical Preparations
Health Care

$VBIV
Financials

Live finance-specific insights

Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results
Transitioning HBV cure programs into multiple late-stage combination studies with interim results throughout 2024 and 2025 informing Company's registrational strategy Integrating R&D, manufacturing and commercial upsides by acquiring full intellectual property rights of BRII-179 and expanding its manufacturing footprint Prioritizing company resources with a robust cash balance of US$376 million supporting operations until 2027 Company to host a conference call (English session) on March 25 at 8:30 AM ET / 8:30 PM HKT DURHAM, N.C. and BEIJING, March 22, 2024 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a biotechnology company developing therapie
3/22/24 7:00:00 AM ET
$ANTX
$VBIV
$VIR
Biotechnology: Pharmaceutical Preparations
Health Care
Biotechnology: Biological Products (No Diagnostic Substances)
VBI Vaccines Reports Third Quarter 2023 Financial Results
PreHevbrio (Hepatitis B Vaccine [Recombinant]) global net revenue increased 52% quarter-over-quarter from Q2 to Q3 2023 Continued execution across earlier-stage pipeline, including: Initiation of Phase 2b study of VBI-1901 in recurrent glioblastoma (GBM) patients Interim Phase 1 data announced for pan-coronavirus candidate, VBI-2901 Novel mRNA-launched eVLP platform technology announced VBI Vaccines Inc. (NASDAQ:VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today provided a business update and announced financial results for the quarter ended September 30, 2023. "In Q3, we were focused on pip
11/14/23 4:05:00 PM ET
$VBIV
Biotechnology: Pharmaceutical Preparations
Health Care
Brii Biosciences Provides Corporate Updates and Reports 2023 Interim Results
First patient dosed in a PEG-IFN-α controlled BRII-835 + PEG-IFN-α combination Phase 2 study for HBV functional cure First of several studies to investigate the potential of BRII-179 in enriching patients with strong intrinsic anti-HBsAg responses for curative treatments to start before the end of 2023 Regulatory submissions and preparation for launches of PreHevbri® in APAC countries and regions are underway Near-term revenue opportunities with PreHevbri® and strong balance sheet supporting operations through 2026 Company to host earnings call on August 22 at 8:00 PM ET / August 23 at 8:00 AM HKT and an HBV R&D Day on August 24 from 1:00-2:30 PM HKT DURHAM, N.C. and BEIJING, Aug. 22, 2023 /
8/22/23 10:00:00 AM ET
$VBIV
$VIR
Biotechnology: Pharmaceutical Preparations
Health Care
Biotechnology: Biological Products (No Diagnostic Substances)

Brii Biosciences Provides Latest Clinical Development and Corporate Updates
Company extends BRII-179 license to global rights and introduces preventive vaccine, PreHevbri® in Greater China and Asia Pacific markets New data from BRII-835 + PEG-IFN-α study have demonstrated that robust anti-HBs antibody responses at the end of treatment are associated with sustained HBsAg loss 24 weeks post treatment Company owns exclusive global rights of BRII-693 in development for difficult-to-treat carbapenem-resistant Gram-negative bacterial infections Dr. David Margolis appointed as Chief Medical Officer to lead organization's late-stage clinical programs towards commercialization DURHAM, N.C. and BEIJING, July 5, 2023 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the
7/5/23 7:18:00 PM ET
$ANTX
$VBIV
$VIR
Biotechnology: Pharmaceutical Preparations
Health Care
Biotechnology: Biological Products (No Diagnostic Substances)
VBI Vaccines Appoints Vaughn Himes to Board of Directors
VBI Vaccines Inc. (NASDAQ:VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that Vaughn B. Himes, Ph.D., Chief Technical Officer of Seagen Inc., has joined VBI's Board of Directors. Dr. Himes has a 30+-year successful track record in biotechnology strategic direction and change management, driving value creation and growth at both small and large biopharmaceutical companies. "Vaughn brings extensive CMC (chemistry, manufacturing, and controls), product development, quality, and strategic business transformation expertise to VBI," said Jeff Baxter, VBI's President and CEO. "In his current and previo
4/25/23 8:00:00 AM ET
$VBIV
Biotechnology: Pharmaceutical Preparations
Health Care
VBI Vaccines Announces Increased Focus on Hepatitis B, Organizational Changes, and Reverse Stock Split
VBI will continue to heavily prioritize making a difference in both prevention and treatment of hepatitis B (HBV) with PreHevbrio™ [Hepatitis B Vaccine (Recombinant)] and immunotherapeutic candidate VBI-2601 Cost-saving measures expected to reduce quarterly operating expenses and headcount by 30-35% VBI to effect a 1-for-30 reverse stock split of its issued and outstanding common shares – shares are expected to trade on the new split-adjusted basis as of commencement of trading on April 12, 2023 VBI Vaccines Inc. (NASDAQ:VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced plans to focus the C
4/4/23 8:00:00 AM ET
$VBIV
Biotechnology: Pharmaceutical Preparations
Health Care

VBI Vaccines Presents Early Tumor Response Data From Randomized Controlled Phase 2b Study Of VBI-1901 In Recurrent Glioblastoma; Early Data From Patients Eligible For Evaluation At Week 12 Show Two Observations Of Stable Disease, Indicating No Tumor Progression, In VBI-1901 Treatment Arm

Chat with this insight

Recent Analyst Ratings for $VBIV

$VBIV Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

VBI Vaccines downgraded by Raymond James with a new price target

Raymond James reiterated coverage on VBI Vaccines with a new price target

Jefferies resumed coverage on VBI Vaccines with a new price target

$VBIV Press Releases

Fastest customizable press release news feed in the world

VBI Vaccines Provides an Update on its Restructuring Proceedings

VBI Vaccines Initiates Restructuring Proceedings Under CCAA to Implement a Review of its Strategic Alternatives

VBI Vaccines Announces Results of Annual General Meeting

$VBIV Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13D/A filed by VBI Vaccines Inc. New (Amendment)

SEC Form SC 13D/A filed by VBI Vaccines Inc. New (Amendment)

SEC Form SC 13G filed by VBI Vaccines Inc. New

$VBIV Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Braga Damian

SEC Form 4 filed by Dewilde Michel

SEC Form 4 filed by Beattie Nell

$VBIV Market Insights

Live Market Insights

VBI Vaccines Reports New Tumor Response Data From Ongoing Randomized Controlled Phase 2b Study Of VBI-1901 For Patients With Recurrent Glioblastoma

VBI Vaccines To Present New Interim Phase 2b Data From VBI-1901 In Recurrent Glioblastoma Patients In Poster Presentation At 2024 ASCO Annual Meeting

VBI Vaccines Q1 EPS $(0.73) Up From $(3.22) YoY, Sales $1.21M Up From $485.00K YoY

$VBIV Financials

Live finance-specific insights

Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results

VBI Vaccines Reports Third Quarter 2023 Financial Results

Brii Biosciences Provides Corporate Updates and Reports 2023 Interim Results

$VBIV Leadership Updates

Live Leadership Updates

$VBIV SEC Filings

Brii Biosciences Provides Latest Clinical Development and Corporate Updates

VBI Vaccines Appoints Vaughn Himes to Board of Directors

VBI Vaccines Announces Increased Focus on Hepatitis B, Organizational Changes, and Reverse Stock Split

VBI Vaccines Inc. New filed SEC Form 8-K: Bankruptcy or Receivership, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial Statements and Exhibits

VBI Vaccines Inc. New filed SEC Form 8-K: Bankruptcy or Receivership, Creation of a Direct Financial Obligation, Other Events

VBI Vaccines Inc. New filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits

Recent Analyst Ratings for
$VBIV

$VBIV
Analyst Ratings

$VBIV
Press Releases

$VBIV
Large Ownership Changes

$VBIV
Insider Trading

$VBIV
Market Insights

$VBIV
Financials

$VBIV
Leadership Updates

$VBIV
SEC Filings